gadopentetate dimeglumine (cont.)
IN THIS ARTICLE
What should I discuss with my health care provider before receiving gadopentetate dimeglumine (Magnevist)?
Gadopentetate dimeglumine can cause a life-threatening condition in people with advanced kidney disease. The symptoms of this condition include:
Before receiving this medication, tell your doctor if you have kidney disease or if you are on dialysis. You may not be able to receive gadopentetate dimeglumine.
To make sure you can safely receive this medication, tell your doctor if you have any of these other conditions:
FDA pregnancy category C. It is not known whether gadopentetate dimeglumine will harm an unborn baby. Before you receive this medication, tell your doctor if you are pregnant.
Gadopentetate dimeglumine can pass into breast milk and may harm a nursing baby. Do not receive this medication without telling your doctor if you are breast-feeding a baby.
How is gadopentetate dimeglumine used (Magnevist)?
Gadopentetate dimeglumine is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting during your MRI.
Your doctor or other healthcare provider may want to watch you for a short time after your test is over. This is to make sure you do not have any unwanted side effects or delayed reactions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Find out what women really need.